Huasen Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 62.98 million yuan. The company's total operating revenue was 414 million yuan, a decrease of 28.36 million yuan compared with the same period last year, down 6.42 percent year on year. Net cash inflow from operating activities was 54.66 million yuan. The latest asset-liability ratio was 14.77 percent, gross margin was 59.26 percent, return on equity was 3.62 percent, and diluted earnings per share was 0.15 yuan.
Chongqing Pharscin Pharmaceutical Co LtdRevenue declined 6.42% year-on-year, though net profit was 62.98 million yuan.
